General Information of Drug (ID: DMIY68N)

Drug Name
US8921389, 22 Drug Info
Synonyms CHEMBL3639707; SCHEMBL12503102; DKTMWXXXKCITJR-UHFFFAOYSA-N; BDBM141566; US8921389, 22; 3-[(1,3-Dibenzyl-5-hydroxy-2-oxo-8-pyridin-3-yl-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-propionic acid
Cross-matching ID
PubChem CID
60152635
TTD Drug ID
DMIY68N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FG-4592 DM4XSQ2 Anaemia 3A90 Phase 3 [2]
US9422240, 1-298 DMH7DL5 N. A. N. A. Patented [3]
US8598210, Table XV, 2 DMDK98P N. A. N. A. Patented [4]
US8536181, A41 DMF9LNO N. A. N. A. Patented [5]
US8598210, Table XV, 5 DMEU5ST N. A. N. A. Patented [6]
US8536181, C17 DMRTL63 N. A. N. A. Patented [7]
US8598210, Table XV, 4 DM3XWMO N. A. N. A. Patented [8]
US8921389, 210 DME1A80 N. A. N. A. Patented [9]
US8536181, C35 DMAM51Z N. A. N. A. Patented [5]
US10100051, Compound 2 DMWESZ1 N. A. N. A. Patented [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF-prolyl hydroxylase 2 (HPH-2) TT9ISBX EGLN1_HUMAN Inhibitor [1]

References

1 Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase. US8921389.
2 Crystalline forms of a prolyl hydroxylase inhibitor. US9115085.
3 Partially saturated nitrogen-containing heterocyclic compound. US9422240.
4 Prolyl hydroxylase inhibitors and methods of use. US9598370.
5 Prolyl hydroxylase inhibitors. US8536181.
6 Prolyl hydroxylase inhibitors and method of use. US8722895.
7 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha. US8778412.
8 Prolyl hydroxylase inhibitors and methods of use. US8598210.
9 Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170.
10 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051.